CAPRICOR THERAPEUTICS, INC. Revenue from Contract with Customer, Including Assessed Tax
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-03-17
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-12-31 was $11.13M, a 7.92% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-09-30 was $2.26M, a 63.44% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-06-30 was $3.97M, a 1.38% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-03-31 was $4.91M, a 64.29% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $22.27M, a 11.55% decline from fiscal 2023.
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $25.18M, a 886.81% increase from fiscal 2022.
- CAPRICOR THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $2.55M, a 941.85% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 | ||||||
| 2024-12-31 | $11.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $13.39M derived: sum of 2 quarters · filed 2026-03-17 | $17.36M derived: sum of 3 quarters · filed 2026-03-17 | $22.27M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $2.26M 10-Q · filed 2025-11-10 | $6.23M derived: sum of 2 quarters · filed 2025-11-10 | $11.14M 10-Q · filed 2025-11-10 | $23.23M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $3.97M 10-Q · filed 2025-08-11 | $8.88M 10-Q · filed 2025-08-11 | $20.97M derived: sum of 3 quarters · filed 2025-08-11 | $27.15M derived: sum of 4 quarters · filed 2025-08-11 | |||
| 2024-03-31 | $4.91M 10-Q · filed 2025-05-14 | $16.99M derived: sum of 2 quarters · filed 2025-05-14 | $23.18M derived: sum of 3 quarters · filed 2025-05-14 | $27.10M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $18.27M derived: sum of 2 quarters · filed 2025-03-26 | $22.19M derived: sum of 3 quarters · filed 2025-03-26 | $25.18M 10-K · filed 2025-03-26 | |||
| 2023-09-30 | $6.19M 10-Q · filed 2024-11-14 | $10.10M derived: sum of 2 quarters · filed 2024-11-14 | $13.09M 10-Q · filed 2024-11-14 | $14.05M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $3.92M 10-Q · filed 2024-08-08 | $6.90M 10-Q · filed 2024-08-08 | $7.86M derived: sum of 3 quarters · filed 2024-08-08 | $9.46M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $2.99M 10-Q · filed 2024-05-14 | $3.95M derived: sum of 2 quarters · filed 2024-05-14 | $5.54M derived: sum of 3 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $2.60M 10-K · filed 2023-03-17 | $959.90K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $2.55M derived: sum of 2 quarters · filed 2024-03-11 | $2.55M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $1.59M 10-Q · filed 2023-11-14 | $1.59M 10-Q · filed 2023-11-14 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $204.08K derived: sum of 3 quarters · filed 2023-03-17 | $244.90K 10-K · filed 2023-03-17 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $204.08K derived: sum of 2 quarters · filed 2022-11-10 | $244.90K 10-Q · filed 2022-11-10 | $302.73K derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $204.08K 10-Q · filed 2022-08-12 | $244.90K 10-Q · filed 2022-08-12 | $302.73K derived: sum of 3 quarters · filed 2022-08-12 | $319.59K derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2021-03-31 | $40.82K 10-Q · filed 2022-05-11 | $98.65K derived: sum of 2 quarters · filed 2022-05-11 | $115.51K derived: sum of 3 quarters · filed 2022-05-11 | $165.37K derived: sum of 4 quarters · filed 2022-05-11 | |||
| 2020-12-31 | $57.83K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $74.69K derived: sum of 2 quarters · filed 2022-03-11 | $124.56K derived: sum of 3 quarters · filed 2022-03-11 | $310.25K 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $16.86K 10-Q · filed 2021-11-12 | $66.73K derived: sum of 2 quarters · filed 2021-11-12 | $252.42K 10-Q · filed 2021-11-12 | $474.52K derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $49.86K 10-Q · filed 2021-08-13 | $235.56K 10-Q · filed 2021-08-13 | $457.66K derived: sum of 3 quarters · filed 2021-08-13 | $599.73K derived: sum of 4 quarters · filed 2021-08-13 | |||
| 2020-03-31 | $185.69K 10-Q · filed 2021-05-14 | $407.79K derived: sum of 2 quarters · filed 2021-05-14 | $549.86K derived: sum of 3 quarters · filed 2021-05-14 | $960.22K derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | $222.10K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $364.17K derived: sum of 2 quarters · filed 2021-03-15 | $774.52K derived: sum of 3 quarters · filed 2021-03-15 | $1.01M 10-K · filed 2021-03-15 | |||
| 2019-09-30 | $142.07K 10-Q · filed 2020-11-13 | $552.42K derived: sum of 2 quarters · filed 2020-11-13 | $782.93K 10-Q · filed 2020-11-13 | $1.43M derived: sum of 4 quarters · filed 2020-11-13 | |||
| 2019-06-30 | $410.35K 10-Q · filed 2020-08-10 | $640.86K 10-Q · filed 2020-08-10 | $1.29M derived: sum of 3 quarters · filed 2020-08-10 | $1.51M derived: sum of 4 quarters · filed 2020-08-10 | |||
| 2019-03-31 | $230.50K 10-Q · filed 2020-05-15 | $878.59K derived: sum of 2 quarters · filed 2020-05-15 | $1.10M derived: sum of 3 quarters · filed 2020-05-15 | $1.50M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $648.08K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $867.33K derived: sum of 2 quarters · filed 2020-03-27 | $1.27M derived: sum of 3 quarters · filed 2020-03-27 | $1.67M 10-K · filed 2020-03-27 | |||
| 2018-09-30 | $219.25K 10-Q · filed 2019-11-08 | $623.21K derived: sum of 2 quarters · filed 2019-11-08 | $1.02M 10-Q · filed 2019-11-08 | ||||
| 2018-06-30 | $403.96K 10-Q · filed 2019-08-08 | $287.30K 10-Q · filed 2018-08-13 | $804.02K 10-Q · filed 2019-08-08 | $594.05K 10-Q · filed 2018-08-13 | |||
| 2018-03-31 | $400.07K 10-Q · filed 2019-05-14 | ||||||
| 2017-12-31 | $2.67M 10-K · filed 2019-03-29 | ||||||
| 2017-06-30 | $312.87K 10-Q · filed 2018-08-13 | $510.08K 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |